Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

Prostate

Volumn 36, Issue 2, 1998, Pages 129-138

  Peshwa, Madhusudan V ^a   Shi, Jia Dong ^a   Ruegg, Curtis ^a   Laus, Reiner ^a   Van Schooten, Wim C A ^a  

^a Dendreon Corporation   (United States)

Author keywords

CTL; Dendritic cells; Immunotherapy; PAP; Prostate cancer; Prostatic acid phosphatase

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CD8 ANTIGEN; GENE PRODUCT; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CARCINOGENESIS; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; RNA PROBE; TARGET CELL; TUMOR CELL CULTURE; TUMOR REGRESSION;

ACID PHOSPHATASE; ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HLA-A2 ANTIGEN; HUMANS; MALE; PEPTIDE FRAGMENTS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 2642640476     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980701)36:2<129::AID-PROS8>3.0.CO;2-D     Document Type: Article

References (52)

1. Grabbe S, Beissert S, Schwarz T, Granstein RD: Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol Today 1995;16:117-121.
2. Guery J-C, Adorini L: Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J Immunol 1995;154:536-544.
3. Borrow P, Evans CF, Oldstone MBA: Virus-induced immunosuppression: Immune system-mediated desctruction of virus-infected dendritic cells results in generalized immune suppression. J Virol 1995;69:1059-1070.
4. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT: Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1995;1:1297-1302.
5. Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.
6. Walter EA, Greenberg PD, Gilbert MJ, Flinch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1043.
7. Macatonia SE, Patterson S, Knight SC: Primary proliferative and cytoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 1991;74:399-406.
8. Steinman RM, Witmer-Pack M, Inaba K: Dendritic cells: Antigen presentation, accessory function and clinical relevance. In Kamperdijk EW (ed): "Dendritic Cells in Fundamental and Clinical Immunology," New York: Plenum Press, 1993:1-9.
9. Nair S, Babu JS, Dunham RG, Kanda P, Burke RL, Rouse BT: Induction of primary, antiviral cytotoxic, and proliferation responses with antigens administered via dendritic cells. J Virol 1993;67:4062-4069.
10. + cytotoxic T lymphocytes by dendritic cells. J Exp Med 1987;166:182-194.
11. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105-2109.
12. + CTLs from naive precursors. J Immunol 1994;153:996-1003.
13. Bakker ABH, Marland G, de Boer AJ, Huijbens RJF, Danen EHJ, Adema GJ, Figdor CG: Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995;55:5330-5334.
14. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B: Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-2483.
15. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B cell lymphoma using autologous antigen pulsed dendritic cells. Nat Med 1996;2:52-58.
16. Tjoa B, Erickson S, Barren R III, Ragde H, Kenny G, Boynton A, Murphy G: In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995;27:63-69.
17. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
18. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP: Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997;32:272-278.
19. Gutman E, Sproul E, Gutman A: Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936;28:485.
20. Kuciel R, Mazurkiewicz A, Ostrowski W, Stachura J, Steuden I, Szkudlarek J, Radzikowski C: Characterization of anti-prostatic acid phosphatase monoclonal antibody and its medical significance. Biotechnol Appl Biochem 1988;10:257-272.
21. Lam K, Li C, Yam L, Sun T, Lee G, Ziesmer S: Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 1989;15:13-21.
22. Solin T, Kontturi M, Pohlmann R, Vihko P: Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analysis. Biochim Biophys Acta 1990;1048:72-77.
23. Jacobs E, Haskell C: Clinical use of tumor markers in oncology. Curr Probl Cancer 1991;15:299-360.
24. Vihko P, Virkkunen P, Henttu P, Roiko K, Solin T, Huhtala M: Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatases. FEBS Lett 1988;236:275-281.
25. Rammensee H-G, Flak K, Rotzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993;11:213-244.
26. + cytotoxic T-lymphocytes for adoptive immunotherapy. Biotechnol Bioeng 1996;50:529-540.
27. Salter RD, Howell DN, Cresswell P: Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985;21:235-246.
28. Koenig S, Woods RM, Brewah YA, Newell AJ, Jones GM, Boone E, Adelsberger JW, Baseler MW, Robinson SM, Jacobson S: Characterization of MHC class I restricted cytotoxic T cell responses to Tax in HTLV-1 infected patients with neurologic disease. J Immunol 1993;156:3874-3883.
29. Elovaara I, Koeing S, Brewah Y, Woods RM, Lehky T, Jacobson S: High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. J Exp Med 1993;177:1567-1573.
30. Feltkamp MCW, Vierboom MPM, Kast WM, Melief CJM: Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol Immunol 1994;31:1391-1401.
31. American Cancer Society, California Division, and Public Health Institute, California Cancer Registry: "California Cancer Facts and Figures, 1998," American Cancer Society, California Division, Oakland, CA, September 1997.
32. Crawford E, Eisenberger M, McLeod D, Spaulding J, Benson R, Dorr A, Blumenstein B, Davis M, Goodman P: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
33. Small E, Srinivas S: The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected advanced prostate cancer patients. Cancer 1995;76:1428-1434.
34. Myers C, Cooper M, Stein C, LaRocca R, Walther M, Weiss G, Chyke P, Dawson N, Steinberg S, Uhrich M: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992;10:881-889.
35. Dong J-T, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p 11.2. Science 1995;268:884-886.
36. Xue B-H, Zhang Y, Sosman JA, Peace DJ: Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997;30:73-78.
37. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R: Induction of tissue specific autoimmune prostatitis with prostatic acid phosphatase immunization. J Immunol 1997;159:3113-3117.
38. Mehta-Damani A, Markowicz S, Engelman EG: Generation of antigen-specific CD4+ T cell lines from naive precursors. Eur J Immunol 1995;25:1206-1211.
39. + cytotoxic T lymphocytes from naive precursors. J Immunol 1994;153:996-1003.
40. Liu LM, MacPherson GG: Antigen acquisition by dendritic cells: Intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo. J Exp Med 1993;177:1299-1307.
41. Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.
42. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-241.
43. Stevens EJ, Jacknin L, Robbins PF, Kawakami Y, Gamil ME, Rosenberg SA, Yannelli JR: Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. J Immunol 1995;154:762-771.
44. Dupuis M, Peshwa MV, Benike C, Kundu SK, Engelman EG, van Schooten WCA: Generation of HIV peptide-specific primary immune response from peripheral blood of AIDS patients using allogeneic dendritic cells from healthy sibling donors. AIDS Res Hum Retroviruses 1997;13:33-39.
45. Kundig TM, Bachmann MF, Oehen S, Hoffmann UW, Simard JJL, Kalberer CP, Pircher H, Ohashi PS, Hengartner H, Zinkernagel RM: On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci USA 1996;93:9716-9723.
46. Young JW, Steinman RM: Accessory cell requirements for the mixed-leukocyte reaction and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells. Cell Immunol 1988;111:167-182.
47. Markowicz S, Engleman EG: Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990;85:955-961.
48. Macatonia SE, Patterson S, Knight SC: Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 1991;74:399-406.
49. Thomas R, Lipsky PE: Human peripheral blood dendritic cell subsets. J Immunol 1994;153:4016-4028.
50. van Schooten WCA, Strang G, Palathumpat V: Biological properties of dendritic cells: Implications to their use in the treatment of cancer. Mol Med Today 1997;3:254-260.
51. + cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells. Cell Transplant 1998;7:1-9.
52. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, Rosenberg SA: Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-2265.